IVIS Spectrum Imaging System

IVIS 光谱成像系统

基本信息

批准号：
7595434
负责人：
ANNA MOORE
金额：
$ 34.11万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-05-01 至 2010-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7595434
关键词：
Animals Area Arts Biological Testing Bioluminescence Biomedical Research Boston Brain Diseases Cardiovascular Pathology Characteristics Communities Data Detection Development Diabetes Mellitus Emerging Technologies Environment Experimental Models Fluorescence Functional Magnetic Resonance Imaging Funding General Hospitals Image In Vitro Institution Interdisciplinary Study Islets of Langerhans Life Magnetic Resonance Imaging Magnetoencephalography Malignant Neoplasms Massachusetts Modality Multimodal Imaging Mus Operative Surgical Procedures Optics Positron-Emission Tomography Preclinical Drug Evaluation Radiation Relative (related person)Reporter Research Research Project Grants Resolution Resources Signal Transduction Speed System Techniques Time Transplantation bioimaging clinical application cost data acquisition imaging modality in vivo innovation instrumentation light emission molecular imaging nervous system disorder new technology novel optical imaging public health relevance research study success transmission process

项目摘要

DESCRIPTION (provided by applicant): Optical imaging is rapidly becoming one of the most versatile imaging modalities in biomedical research. The advantages of optical imaging compared to other imaging modalities include its non-ionizing low-energy radiation, high sensitivity for detecting objects in the micron range, and continuous data acquisition in real time and in an intact environment. The cost, space, and time demands associated with optical imaging are less than for other imaging modalities, and the speed and relative ease of imaging makes this modality attractive for potential clinical applications. The Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (MGH) strives to develop and apply breakthrough imaging approaches in clinically meaningful ways. Our continuing success relies on the integration of new and emerging technologies into our existing research imaging repertoire, which includes functional and high-resolution magnetic resonance imaging (fMRI and MRI), magnetoencephalography (MEG), positron emission tomography (PET), and homebuilt functional optical imaging instrumentation. New technologies enhance our ability to validate and interpret data from our existing imaging resources and to combine imaging modalities for novel multimodal imaging applications-capabilities that are particularly needed in the emerging field of molecular imaging. We propose to purchase a state-of-the-art optical imaging system capable of 3D molecular imaging in transmission fluorescence, reflectance fluorescence, and bioluminescence modes in vivo, ex vivo, and in vitro. Significant advantages of the optical techniques possible with this system include the potential for multichannel imaging by using multiple probes with different spectral characteristics; quick, easy, and relatively low-cost rapid testing of biological hypotheses and proofs of principle in living experimental models. Importantly, optical bioluminescence imaging has unique advantages for detection of very low levels of signal because of its virtually background-free light emission. With its ease of operation, short acquisition time (typically 10-60 sec), and potential high-throughput format in vitro (microplates) and in vivo (5 mice, 23 cm FOV), this innovative system also provides high-throughput imaging capabilities. The new optical system will be an important resource for many currently funded biomedical imaging research projects. Major projects include studies on neurodenenerative disorders and brain function, cancer, and pancreatic islets in diabetes and transplantation. With the new in vivo optical imaging system and our existing imaging facilities under one roof, we can feasibly perform in-vivo experiments using one or more imaging modalities in succession, or even in parallel. This system will be an invaluable resource for the rich body of interdisciplinary research at the Martinos center and the larger MGH research community, as well as at other institutions in the greater Boston area. PUBLIC HEALTH RELEVANCE: Acquiring of a state-of-the-art in vivo optical imaging system with fluorescence and bioluminescence capabilities will allow for fast, easy and cheap ways to rapidly test biological hypotheses and proofs of principle in living experimental models, which could be further utilized for in vivo drug screening, development of imaging reporters and versatile animal studies in cancer, neurological disorders, diabetes and cardiovascular pathologies.

描述（由申请人提供）：光学成像正在迅速成为生物医学研究中最通用的成像方式之一。与其他成像方式相比，光学成像的优点包括非电离低能辐射、检测微米范围内物体的高灵敏度以及在完整环境中实时连续采集数据。与光学成像相关的成本、空间和时间需求低于其他成像方式，并且成像的速度和相对容易性使得这种方式对潜在的临床应用具有吸引力。马萨诸塞州总医院 (MGH) 的 Athinoula A. Martinos 生物医学成像中心致力于以具有临床意义的方式开发和应用突破性成像方法。我们的持续成功依赖于将新兴技术整合到我们现有的研究成像技术中，其中包括功能性和高分辨率磁共振成像（fMRI 和 MRI）、脑磁图（MEG）、正电子发射断层扫描（PET）和自制功能性成像技术。光学成像仪器。新技术增强了我们验证和解释现有成像资源中的数据的能力，以及将成像模式结合起来以实现新型多模态成像应用的能力，这些能力在新兴的分子成像领域尤其需要。我们建议购买最先进的光学成像系统，能够在体内、离体和体外以透射荧光、反射荧光和生物发光模式进行 3D 分子成像。该系统的光学技术的显着优点包括通过使用具有不同光谱特性的多个探头进行多通道成像的潜力；快速、简单且相对低成本地在活体实验模型中快速测试生物学假设和原理证明。重要的是，光学生物发光成像由于其几乎无背景的光发射，在检测极低水平的信号方面具有独特的优势。由于操作简便、采集时间短（通常为 10-60 秒）以及体外（微孔板）和体内（5 只小鼠，23 cm FOV）潜在的高通量格式，该创新系统还提供高通量成像功能。新的光学系统将成为许多目前资助的生物医学成像研究项目的重要资源。主要项目包括神经退行性疾病和脑功能、癌症以及糖尿病和移植中的胰岛的研究。借助新的体内光学成像系统和我们现有的成像设施，我们可以连续甚至并行地使用一种或多种成像方式进行体内实验。该系统对于马蒂诺斯中心和更大的麻省总医院研究界以及大波士顿地区其他机构的丰富的跨学科研究来说将是宝贵的资源。公共健康相关性：获得具有荧光和生物发光功能的最先进的体内光学成像系统将允许以快速、简单和廉价的方式在活体实验模型中快速测试生物学假设和原理证明，这可能是进一步用于体内药物筛选、成像报告基因的开发以及癌症、神经系统疾病、糖尿病和心血管病理学的多功能动物研究。

项目成果

期刊论文数量（20）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Image-guided breast tumor therapy using a small interfering RNA nanodrug.

DOI：
10.1158/0008-5472.can-10-2070
发表时间：
2010-10-01
期刊：
Cancer research
影响因子：
11.2
作者：
Kumar M;Yigit M;Dai G;Moore A;Medarova Z
通讯作者：
Medarova Z

Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma.

DOI：
10.1002/ijc.28499
发表时间：
2014-04-01
期刊：
INTERNATIONAL JOURNAL OF CANCER
影响因子：
6.4
作者：
Ghosh, Subrata K.;Yigit, Mehmet V.;Uchida, Masashi;Ross, Alana W.;Barteneva, Natalie;Moore, Anna;Medarova, Zdravka
通讯作者：
Medarova, Zdravka

The natural compound obtusaquinone targets pediatric high-grade gliomas through ROS-mediated ER stress.